JHM Dean/CEO Paul Rothman appointed to second term – A Message from JHU President Ronald J. Daniels

Dear Faculty, Students, and Staff:

I am delighted to announce the appointment of Dr. Paul Rothman to a second term as CEO of Johns Hopkins Medicine and dean of Johns Hopkins University School of Medicine. With full support from the boards of Johns Hopkins Medicine, Johns Hopkins Health System, and Johns Hopkins University, his six-year term began this summer.

Over the past five years, Paul has provided exceptional leadership, advancing our clinical, research, and educational missions in the midst of a turbulent landscape for academic medicine. Conversations with students, faculty, staff, and administrators throughout Johns Hopkins Medicine confirmed our strong belief that Paul possesses and articulates a sharp and nuanced understanding of this institution's role in delivering the highest quality care to patients at home and abroad, producing new discoveries and embracing research agendas that are critical to the health of the world, and educating the next generation of premier clinicians and scientists.

As dean/CEO, Paul has recruited and appointed an outstanding complement of leaders in directorships across the School of Medicine, in the Dean's Office, and—in partnership with Ron Peterson, president of the Johns Hopkins Health System—across the health system. Paul initiated the development and implementation of Johns Hopkins Medicine's first enterprisewide strategic plan, providing key guidance on the shared principles and aspirations that help align and integrate JHM. He worked closely with Ron Peterson and other key colleagues to implement key operational changes, including the successful rollout of the electronic medical records system EPIC, and the smooth transition to the Charlotte R. Bloomberg Children's Center and the Sheik Zayed Tower, state-of-the-art clinical facilities. And he has made substantial investments in precision medicine, while simultaneously developing Centers of Excellence that will apply these principles to medical practice, advancing our potential to fundamentally alter patient outcomes.

At a time when funding for basic and clinical research at all levels has been constrained, Paul has demonstrated his unwavering commitment to research and discovery. He has partnered with fellow deans and directors to foster universitywide support for early- and midcareer scientists, investments that have led to new NIH grants and novel collaborations across our divisions. Under his leadership, the School of Medicine supported the 2015 launch of Johns Hopkins Technology Ventures to aid our faculty, students, and staff in translating their discoveries into market-ready treatments. Paul has also worked to drive the Bloomberg Distinguished Professorships program, recruiting a cadre of exceptional interdisciplinary researchers and clinicians who are helping to sustain our research excellence.

Time and again during the reappointment evaluation process, colleagues from across our institution described Paul as the consummate clinician-scientist, a leader who has the skill and vision to see and advance priorities in both research and clinical practice without losing sight of the joy of medicine. He is an exemplary partner and colleague, and we are delighted that our health system, our university, and our School of Medicine will benefit from his continued leadership over the next six years.

Please join me in congratulating Paul on his reappointment.

Sincerely,

Ronald J. Daniels
President